- Home
- GLMD vs CLDI Comparison
GLMD vs CLDI Comparison
Compare GLMD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- CLDI
- Stock Information
- Founded
- GLMD 2000
- CLDI 2014
- Country
- GLMD Israel
- CLDI United States
- Employees
- GLMD N/A
- CLDI N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLMD Health Care
- CLDI Health Care
- Exchange
- GLMD Nasdaq
- CLDI Nasdaq
- Market Cap
- GLMD 8.0M
- CLDI 8.7M
- IPO Year
- GLMD 2014
- CLDI N/A
- Fundamental
- Price
- GLMD $1.59
- CLDI $1.60
- Analyst Decision
- GLMD Hold
- CLDI
- Analyst Count
- GLMD 1
- CLDI 0
- Target Price
- GLMD N/A
- CLDI N/A
- AVG Volume (30 Days)
- GLMD 81.5K
- CLDI 141.6K
- Earning Date
- GLMD 11-13-2025
- CLDI 11-11-2025
- Dividend Yield
- GLMD N/A
- CLDI N/A
- EPS Growth
- GLMD N/A
- CLDI N/A
- EPS
- GLMD N/A
- CLDI N/A
- Revenue
- GLMD N/A
- CLDI N/A
- Revenue This Year
- GLMD N/A
- CLDI N/A
- Revenue Next Year
- GLMD N/A
- CLDI N/A
- P/E Ratio
- GLMD N/A
- CLDI N/A
- Revenue Growth
- GLMD N/A
- CLDI N/A
- 52 Week Low
- GLMD $1.15
- CLDI $1.41
- 52 Week High
- GLMD $4.81
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- GLMD 58.87
- CLDI 43.90
- Support Level
- GLMD $1.35
- CLDI $1.41
- Resistance Level
- GLMD $1.63
- CLDI $1.68
- Average True Range (ATR)
- GLMD 0.09
- CLDI 0.08
- MACD
- GLMD 0.02
- CLDI 0.05
- Stochastic Oscillator
- GLMD 76.67
- CLDI 66.74
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.